Harbor Capital Advisors Inc. Takes Position in Aura Biosciences, Inc. (NASDAQ:AURA)

Harbor Capital Advisors Inc. purchased a new position in shares of Aura Biosciences, Inc. (NASDAQ:AURA) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 25,741 shares of the company’s stock, valued at approximately $151,000. Harbor Capital Advisors Inc. owned about 0.05% of Aura Biosciences at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of AURA. BNP Paribas Financial Markets bought a new stake in Aura Biosciences during the 4th quarter worth approximately $50,000. GAMMA Investing LLC grew its position in Aura Biosciences by 5,766.9% during the 1st quarter. GAMMA Investing LLC now owns 9,739 shares of the company’s stock worth $57,000 after acquiring an additional 9,573 shares during the last quarter. ProShare Advisors LLC bought a new stake in Aura Biosciences during the 4th quarter worth approximately $127,000. Harvest Investment Services LLC bought a new stake in Aura Biosciences during the 4th quarter worth approximately $133,000. Finally, AlphaQuest LLC bought a new stake in Aura Biosciences during the 4th quarter worth approximately $136,000. 96.75% of the stock is currently owned by institutional investors.

Aura Biosciences Stock Performance

NASDAQ:AURA opened at $6.42 on Monday. The stock’s fifty day moving average price is $5.76 and its two-hundred day moving average price is $7.02. Aura Biosciences, Inc. has a 52-week low of $4.35 and a 52-week high of $12.38. The company has a market cap of $322.73 million, a price-to-earnings ratio of -3.71 and a beta of 0.42.

Aura Biosciences (NASDAQ:AURA) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.08). On average, equities analysts predict that Aura Biosciences, Inc. will post -1.66 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently commented on AURA. HC Wainwright upgraded Aura Biosciences to a “buy” rating and set a $22.00 price target on the stock in a research report on Wednesday, May 28th. JMP Securities reaffirmed a “market outperform” rating and set a $19.00 price objective on shares of Aura Biosciences in a report on Friday, May 23rd. Finally, Citigroup reaffirmed an “outperform” rating on shares of Aura Biosciences in a report on Wednesday, March 26th. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $22.00.

Insider Activity

In related news, Director David Michael Johnson purchased 20,000 shares of the business’s stock in a transaction dated Friday, May 16th. The shares were bought at an average price of $4.90 per share, with a total value of $98,000.00. Following the purchase, the director now directly owns 166,167 shares in the company, valued at $814,218.30. This trade represents a 13.68% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, insider Anthony S. Gibney purchased 50,000 shares of the business’s stock in a transaction dated Friday, May 16th. The stock was bought at an average cost of $4.90 per share, for a total transaction of $245,000.00. Following the purchase, the insider now owns 58,452 shares in the company, valued at $286,414.80. This trade represents a 591.58% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 9,578 shares of company stock valued at $52,067 in the last 90 days. 5.40% of the stock is owned by company insiders.

Aura Biosciences Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.